ZIVO vs. CTNM, DBVT, GALT, VOR, JBIO, LXEO, PBYI, ALLO, IMMP, and EDIT
Should you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include Contineum Therapeutics (CTNM), DBV Technologies (DBVT), Galectin Therapeutics (GALT), Vor Biopharma (VOR), Jade Biosciences (JBIO), Lexeo Therapeutics (LXEO), Puma Biotechnology (PBYI), Allogene Therapeutics (ALLO), Prima BioMed (IMMP), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry.
ZIVO Bioscience vs. Its Competitors
ZIVO Bioscience (NASDAQ:ZIVO) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.
ZIVO Bioscience's return on equity of 0.00% beat Contineum Therapeutics' return on equity.
12.8% of ZIVO Bioscience shares are held by institutional investors. 48.9% of ZIVO Bioscience shares are held by insiders. Comparatively, 11.3% of Contineum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
ZIVO Bioscience has higher earnings, but lower revenue than Contineum Therapeutics. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.
ZIVO Bioscience has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Comparatively, Contineum Therapeutics has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.
In the previous week, ZIVO Bioscience and ZIVO Bioscience both had 2 articles in the media. Contineum Therapeutics' average media sentiment score of 0.94 beat ZIVO Bioscience's score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the news media.
Contineum Therapeutics has a consensus target price of $22.75, indicating a potential upside of 117.70%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Contineum Therapeutics is more favorable than ZIVO Bioscience.
Summary
Contineum Therapeutics beats ZIVO Bioscience on 9 of the 15 factors compared between the two stocks.
Get ZIVO Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZIVO Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:ZIVO) was last updated on 9/1/2025 by MarketBeat.com Staff
Free ZIVO Stock Alerts